---
title: ESP Block in Radical Prostatectomy
nct_id: NCT05170373
overall_status: COMPLETED
phase: NA
sponsor: Istanbul Medeniyet University
study_type: INTERVENTIONAL
primary_condition: Erector Spinae Plane Block
countries: Turkey (Türkiye)
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05170373.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05170373"
ct_last_update_post_date: 2021-12-28
last_seen_at: "2026-05-12T07:05:13.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# ESP Block in Radical Prostatectomy

**Official Title:** Effects of Ultrasound Guided Erector Spinae Plane Block in Radical Prostatectomy Surgery on Pain and Surgical Stress Response

**NCT ID:** [NCT05170373](https://clinicaltrials.gov/study/NCT05170373)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 46
- **Lead Sponsor:** Istanbul Medeniyet University
- **Conditions:** Erector Spinae Plane Block
- **Start Date:** 2019-02-01
- **Completion Date:** 2020-06-01
- **CT.gov Last Update:** 2021-12-28

## Brief Summary

Our study aimed to examine the effects of ultrasound guided erector spinae plane block in radical prostatectomy surgery on pain and surgical stress response, to reduce adrenocortical and sympathetic discharge due to anesthesia and surgery, and to reduce peroperative opioid analgesic consumption.

## Detailed Description

In this study 46 patients between the ages of 30-74, American Society of Anesthesiologists (ASA) score I-II and undergoing radical prostatectomy surgery at T.R. Ministry Of Health İstanbul Göztepe Prof. Dr. Süleyman Yalçın City Hospital were included. The patients were randomly divided into two groups as ESPB applied Group B (n=23) and not Group K (n=23). Patient-controlled analgesia (PCA) was initiated in all patients for postoperative analgesia. Patients' demographic data (age, gender, ASA score), intraoperative hemodynamic data, intraoperative and postoperative additional narcotic consumption, postoperative Numeric Rating Scale (NRS) scores (postoperative 0, 5 and 20 minutes and Then, 1, 3, 6, 12, 18 and 24 h), postoperative nausea-vomiting scores and possible complications related to block and / or surgery were recorded.Intraoperative MAP, HR, SpO2, BIS values of patients in both groups were recorded every 5 minutes. Blood glucose, insulin, cortisol, prolactin and C-reactive protein (CRP) were studied three times; preop morning at 6:00, intraoperative when surgical incision closing and postoperative 24h. in order to evaluate the surgical stress response in the patients.

## Eligibility

- **Minimum age:** 30 Years
- **Maximum age:** 74 Years
- **Sex:** MALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* ASA I-II

Exclusion Criteria:

* diabetes
* coagulopathy
* local anesthetic
* drug allergy
* long hospitalization history,
* hormone disorder
* advanced organ failure
* history of steroid use
* vertebral anomalies
* mental retardation
```

## Arms

- **ESP group** (ACTIVE_COMPARATOR)
- **control group** (NO_INTERVENTION)

## Interventions

- **ESP block** (PROCEDURE) — Before general anesthesia, ESP block was applied from the T12 vertebra level with 10 ml 0.5% bupivacaine HCL 5 ml 2% lidocaine HCL 5 ml 0.9% isotonic NaCl mixture

## Primary Outcomes

- **Numeric Pain Scale** _(time frame: postoperative 24 hours.)_ — Between 1-10. 1: no pain, 10: worst possible pain
- **Blood glucose** _(time frame: postoperative 24 hours.)_ — mg /dL
- **insulin** _(time frame: postoperative 24 hours.)_ — µIU/mL
- **cortisol** _(time frame: postoperative 24 hours.)_ — µg/dL
- **prolactin** _(time frame: postoperative 24 hours.)_ — µg/L
- **C-reactive protein** _(time frame: postoperative 24 hours.)_ — mg/L

## Secondary Outcomes

- **Remifentanil Consumption Speed** _(time frame: 3 hours)_

## Locations (1)

- Istanbul Suleyman Yalcin City Hospital, Istanbul, Turkey (Türkiye)

## Recent Field Changes (last 30 days)

- `outcomes.secondary` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.istanbul suleyman yalcin city hospital|istanbul||turkey (türkiye)` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05170373.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05170373*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*